- PLN63.86m
- PLN77.69m
- PLN95.56m
- 83
- 69
- 56
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.78 | ||
| Price to Tang. Book | 1.81 | ||
| Price to Free Cashflow | 7.87 | ||
| Price to Sales | 0.67 | ||
| EV to EBITDA | 6.3 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 19.19% | ||
| Return on Equity | 12.29% | ||
| Operating Margin | 9.22% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | PLNm | 46.63 | 48.33 | 65.32 | 79.62 | 95.56 | n/a | n/a | 18.88% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +6.09 | -28.99 | +117.44 | +71.48 | +8.6 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.
Directors
- Urszula Grzegorzewska CSU
- Andrzej Grzegorzewski CMG
- Barbara Bieganska VMG
- Dorota Skorupa CAO
- Sebastian Kostecki SUB
- Anna Kowalska SUB
- Elzbieta Mikolajczyk SUB
- Andrzej Mozyszek SUB
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 1st, 2007
- Public Since
- August 31st, 2011
- No. of Employees
- 205
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Warsaw Stock Exchange- Shares in Issue
- 2,456,319
- Address
- ul. Pojezierska 99, LODZ, 91-342
- Web
- https://www.biogened.pl/
- Phone
- +48 426513152
- Auditors
- KPW Audytor sp. zoo
Upcoming Events for BGD
Similar to BGD
Bioceltix SA
Warsaw Stock Exchange
BioMaxima SA
Warsaw Stock Exchange
Cannabis Poland SA
Warsaw Stock Exchange
Celon Pharma SA
Warsaw Stock Exchange
Cosma SA
Warsaw Stock Exchange
FAQ
As of Today at 19:04 UTC, shares in Biogened SA are trading at PLN26.00. This share price information is delayed by 15 minutes.
Shares in Biogened SA last closed at PLN26.00 and the price had moved by +92.59% over the past 365 days. In terms of relative price strength the Biogened SA share price has outperformed the FTSE Global All Cap Index by +80.81% over the past year.
There is no consensus recommendation for this security.
Biogened SA does not currently pay a dividend.
Biogened SA does not currently pay a dividend.
Biogened SA does not currently pay a dividend.
To buy shares in Biogened SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of PLN26.00, shares in Biogened SA had a market capitalisation of PLN63.86m.
Here are the trading details for Biogened SA:
- Country of listing: Poland
- Exchange: WSE
- Ticker Symbol: BGD
Based on an overall assessment of its quality, value and momentum Biogened SA is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biogened SA. Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +42.24%.
As of the last closing price of PLN26.00, shares in Biogened SA were trading +43.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Biogened SA PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at PLN26.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Biogened SA's management team is headed by:
- Urszula Grzegorzewska - CSU
- Andrzej Grzegorzewski - CMG
- Barbara Bieganska - VMG
- Dorota Skorupa - CAO
- Sebastian Kostecki - SUB
- Anna Kowalska - SUB
- Elzbieta Mikolajczyk - SUB
- Andrzej Mozyszek - SUB